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Abstract
The effect on memory processes of inactivation of the M1 gene by an antisense oligodeoxyribonucleotide (aODN) was
investigated in the mouse passive avoidance test. Mice received a single intracerebroventricular (i.c.v.) injection of M1 aODN (0.3,
1.0 or 2.0 nmol per injection), degenerated ODN (dODN) or vehicle on days 1, 4 and 7. An amnesic effect, comparable to that
produced by antimuscarinic drugs, was observed 12, 24, 48 and 72 h after the last i.c.v. aODN injection, whereas dODN and
vehicle, used as controls, did not produce any effect. Reduction in the entrance latency to the dark compartment induced by
aODN disappeared 7 days after the end of aODN treatment, which indicates the absence of any irreversible damage or toxicity
caused by aODN. Quantitative reverse transcription-polymerase chain reaction analysis demonstrated that a decrease in M1
mRNA levels occurred only in the aODN-treated group, being absent in all control groups. Furthermore, a reduction in M1
receptors was observed in the hippocampus of aODN-treated mice. Neither aODN, dODN nor vehicle produced any behavioral
impairment of mice. These results indicate that the integrity and functionality of M1 receptors are fundamental in the modulation
of memory processes. © 1999 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Cholinergic activity has long been associated with
memory processes. Morphological and neurochemical
studies of Alzheimer’s disease, the major type of de-
mentia, revealed marked decreases in the cholinergic
innervation of the cortex and hippocampus (Bartus et
al., 1982; Mash et al., 1985; Whitehouse, 1986). Drugs
involving cholinergic stimulation alleviated cognitive
dysfunctions in Alzheimer’s disease (Bartus et al., 1982)
and in particular M1-selective agonists have been pro-
posed as a promising treatment strategy in this pathol-
ogy (Mash et al., 1985; Whitehouse, 1986; Fisher et al.,
1989; Gualtieri et al., 1995). On the other hand, cho-
linergic blockade produces significant impairments of
cognitive functions. A delay-dependent disruption fol-
lowing treatment with scopolamine and atropine, that
appeared to resemble that occurring spontaneously in
aged subjects and in Alzheimer patients, has been re-
ported (Duetsch, 1971; Bartus and Johnson, 1976).
Animals treated with the M1 selective antagonist piren-
zepine (Hammer et al., 1980), had impaired passive
avoidance learning (in mice) (Caufield et al., 1983) and
impaired spatial learning (Hagan et al., 1987; Hunter
and Roberts, 1988), radial arm maze performance (Sala
et al., 1991) and active avoidance acquisition (Sen and
Bhattacharya, 1991) in rats. Moreover, the M1 selective
antagonists dicyclomine (Nilvebrant and Sparf, 1986)
and S-( )-ET-126 (Ghelardini et al., 1996) were able
to induce amnesia in a mouse passive avoidance task
(Ghelardini et al., 1997b; Matucci et al., 1997).
In order to further investigate the role of the M1
muscarinic receptor subtype in learning and memory
processes, an antisense oligodeoxyribonucleotide
(aODN) able to inactivate M1 gene expression was
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Fig. 1. Dose-response curve of an aODN to M1 gene in the mouse passive-avoidance test. Mice received a single i.c.v. injection of aODN, dODN
or vehicle on day 1, 4 and 7. Training session was performed 24 h after the last i.c.v. injection. The number of mice is inside the column. * PB0.01
in comparison with dODN-treated mice.
used. An aODN is a short segment of synthetic DNA
having a sequence complementary to a portion of
targeted mRNAs preventing translation and:or mediat-
ing mRNA cleavage by the enzyme RNase H. aODNs
specifically bind to targeted mRNAs H and, therefore,
down-regulating the synthesis of the encoded useful
pharmacological tools for exploring a variety of neuro-
biological processes at the molecular level by specifi-
cally turning off gene expression, and can be considered
as a new potential class of ‘informational’ drugs
(Wahlestedt, 1994; Crooke and Bennett, 1996; Galeotti
et al., 1997; Ghelardini et al., 1997a; Meiri et al., 1997).
aODN can transiently inactivate a single gene and,
therefore, can inactivate receptor functions in a more
specific and selective manner than receptor antagonists.
The effects on memory processes of anti-M1 aODN
were evaluated in mice. The aODN was conjugated to
an artificial cationic lipid (DOTAP) used as the vehicle
able to improve aODN intracellular stability (Cap-
accioli et al., 1993) and was administered by intracere-
broventricular (i.c.v.) injection. Vehicle and degener-
ated ODN (dODN, an oligonucleotide accounting for
the eventual aODN aspecific effects) were used as con-
trols.
2. Materials and methods
2.1. Animals
Male Swiss albino mice (24–26 g) from Morini (San
Polo d’Enza, Italy) were used. Fifteen mice were housed
per cage. The cages were placed in the experimental
room 24 h before the test for acclimatization. The
animals were fed a standard laboratory diet and tap
water ad libitum and kept at 2391°C with a 12 h
light–dark cycle, light at 07:00 h.
2.2. Antisense oligonucleotides
Low cell permeability and the high degradation of
natural phosphodiester oligomers are considerable
drawbacks in the application of aODNs both in vitro
and in vivo. To overcome these drawbacks, phospho-
rothioate-capped phosphorodiester oligonucleotides
were used. The above-mentioned compounds are a class
of ODN derivatives shown to maintain more stable and
effective concentrations in the brain when compared
with their unmodified counterpart (Whitesell et al.,
1993). Phosphodiester oligonucleotides (ODNs) pro-
tected by terminal phosphorothioate double sub-
stitution (capped ODNs) against possible exo-
nuclease-mediated degradation were purchased from
Genosys (Cambridge, England) and purified by high-
performance liquid chromatography (HPLC). The 18-
mer antisense ODN 5%-CAC TGA GGT GTT CAT
TGC-3% (phosphorothioate residues are underlined)
complementary to the residues 112-129 of the published
mouse M1 cDNA sequence (Shapiro et al., 1988) and
the 18-mer fully degenerated ODN (dODN) 5%-NNN
NNN NNN NNN NNN NNN-3% (where N is G, or C,
or A, or T and phosphorothioate residues are under-
lined) were vehiculated intracellularly by an artificial
cationic lipid (DOTAP, Boehringer–Mannheim, Ger-
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Fig. 2. Time-course of the amnesic effect induced by an aODN to M1 gene in the mouse passive-avoidance test. Mice received a single i.c.v.
injection of aODN (2 nmol per single i.c.v. injection), dODN (2 nmol per single i.c.v. injection) or vehicle on day 1, 4 and 7. Each value represents
the entrance latency in the retention session. The number of mice ranged from 18 to 24. * PB0.01 in comparison with dODN-treated mice.
many) to enhance both uptake and stability, as de-
scribed previously (Capaccioli et al., 1993; Quattrone et
al., 1994b). aODN or degenerated ODN (100–400 mM)
were preincubated at 37°C for 30 min with 13 mM
DOTAP, sterilized through a 0.2 mm filter and supplied
to mice by i.c.v. injection of a 5 ml solution as described
in the next section.
2.3. GenBank accession numbers
The accession number of the cDNA sequence for the
mouse muscarinic receptor subtype reported in this
paper (M1) is J04192.
2.4. I.c.6. injection of oligonucleotides
Mice were randomly assigned to anti-M1 aODN,
dODN, vehicle, saline or naive group. The antisense
and dODNs were dissolved in a vehicle constituted by
DOTAP. Each group received a single i.c.v. injection
on days 1, 4 and 7 whereas naive animals did not
receive any treatment. I.c.v. administration was per-
formed under ether anesthesia with isotonic saline as
solvent, according to the method described by Haley
and McCormick (1957). During anesthesia, mice were
grasped firmly by the loose skin behind the head. A
hypodermic needle (0.4 mm external diameter) attached
to a 10 ml syringe was inserted perpendicularly through
the skull and no more than 2 mm into the brain of the
mouse, where 5 ml ODNs were then administered. The
injection site was 1 mm to the right or left from the
midpoint on a line drawn through to the anterior base
of the ears. Injections were performed randomly into
the right or left ventricle. To ascertain that ODNs were
administered exactly into the cerebral ventricle, some
mice were injected with 5 ml of diluted 1:10 India ink
and their brains were examined macroscopically after
sectioning. The accuracy of the injection technique was
evaluated with 95% of injections being correct.
2.5. Passi6e a6oidance
The test was performed according to the step-
through method described by Jarvik and Kopp (1967).
The apparatus consists of a two-compartment acrylic
box with a lighted compartment connected to a dark-
ened one by a guillotine door. Mice, as soon as they
entered the dark compartment, received a punishing
electrical shock (0.5 mA, 1 s). The latency times for
entering the dark compartment were measured in the
training test and after 24 h in the retention test. For
memory disruption animals were i.c.v. injected with the
amnesic drugs scopolamine, pirenzepine, dicyclomine
and S-( )-ET 126, administered immediately after ter-
mination of the training session. The maximum entry
latency allowed in the training and retention session
was 60 and 180 s, respectively. The memory degree of
received punishment was expressed as latencies
recorded in the training and retention sessions.
2.6. Hole-board test
The hole board test consists of a 40 cm square plane
with 16 flush-mounted cylindrical holes (diameter 3 cm)
distributed 4 by 4 in an equidistant, grid-like manner.
Mice were placed on the center of the board one by one
and left to move about freely for a period of 5 min
each. Two electric eyes, crossing the plane from mid-
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Fig. 3. Amnesic effect of scopolamine, pirenzepine, dicyclomine and S-( )-ET-126 in the mouse passive-avoidance test. All drugs were injected
immediately after the training session. The number of mice is inside the column. * PB0.01 in comparison with naive or saline-treated mice.
Table 1
Lack of effect of an aODN to M1 gene in the mouse rota-rod test
a
Dose per single i.c.v. injection No. of falls in 30 sTreatment
45 min30 min15 min0 min
2.690.2 1.290.3*Saline 5 ml 3.790.3 0.990.3*
1.590.4*2.890.3 1.090.2*3.690.4Vehicle 5 ml
3.890.4 2.590.4 1.490.3*aODN 1.190.2*2 nmol
1.690.3* 0.790.3*dODN 2 nmol 3.690.3 2.490.4
a Mice were injected with aODN, dODN saline or vehicle on day 1, 4 and 7. Rota-rod was performed 24 h after the last i.c.v. injection. Each
value represents the mean of 15 mice.
* PB0.01 in comparison with the respective pre-test value.
point to midpoint of opposite sides, thus dividing the
plane into four equal quadrants, automatically signaled
the movement of the animals on the surface of the plane
(locomotor activity). Miniature photoelectric cells, in
each of the 16 holes, recorded the exploration of the holes
(head plunging activity) by the mice (exploratory activ-
ity). The test was performed 24 h after the last i.c.v.
injection of aODN or dODN. Naive animals were used
as non pretreated controls.
2.7. Rota-rod test
The apparatus consisted of a base platform and a
rotating rod of 3 cm diameter with a nonslippery surface.
The rod was placed at a height of 15 cm from the base.
The rod, 30 cm in length, was divided into five equal
sections by six disks. Thus up to five mice were tested
simultaneously on the apparatus, with a rod-rotating
speed of 16 rpm. The integrity of motor coordination was
assessed on the basis of the number of falls from the rod
in 30 s according to Vaught et al. (1985). The perfor-
mance time was measured before and 15, 30 and 45 min
after the beginning of test. The test was performed 24 h
after the last i.c.v. injection with aODN or dODN. Naive
animals were used as untreated controls.
2.8. RT-PCR-based analysis of M1 mRNA
Twenty-four hours after the last i.c.v. injection of
vehicle, aODN or degenerated ODN, three mice for each
group were sacrificed and their brains were rapidly
removed and stored (80°C). Mouse brain levels of M1
mRNA were determined by a quantitative RT-PCR
method optimized for other genes (Quattrone et al.,
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1994a, 1995a). Frozen mouse brain samples (0.2–0.3 g
wet wt.) were homogenized in three vol. of RNAzol to
extract total RNA according to the manufacturer’s
instructions. RNA was treated with RQ1 RNase-free
DNase, purified by ethanol precipitation, dissolved in
water containing an RNase inhibitor (RNasin at 1 U:ml)
and reversely transcribed to cDNA with random hexam-
ers. A qualitative PCR reaction was preliminarily carried
out for 30 cycles in a standard hot-start PCR procedure
(Chou et al., 1992) with the primer pairs 5%-CCA CCT
GGC TGC AAT GAA C-3%; residues 102-120 and
5%-GTT GAC TGT CTT GAG CTC TGT G-3%; residues
273-294, according to the M1 cDNA published sequence
(Shapiro et al., 1988). RNase treated before RT or
reverse transcriptase-omitted samples were the negative
PCR controls in order to exclude any possible contam-
ination by endogenous genomic DNA and:or by am-
plified DNA carry-over. Primers 5%-GCG GGA AAT
CGT GCG TGA CAT-3%; residues 2104-2125 and 5%-
GAT GGA GTT GAA GGT AGT TTC GTG-3%;
residues 2409-2432, according to the published sequence
(Ng et al., 1985), were used in the quantitative protocol
for the amplification of b-actin cDNA as an internal
standard (Quattrone et al., 1995b). For both primer
pairs, the three-step PCR cycles consisted of 1 min
denaturation at 92°C, 1 min annealing at 58°C and 1 min
extension at 72°C. PCR products were electrophoresed
on 2% agarose gel and the M1 product was first identified
by sequencing with the fmol sequencing kit (Promega,
Madison, WI). For quantitative analysis, different vol-
umes of M1 or b-actin cDNA were separately amplified
for 30 cycles of PCR and the resulting agarose bands were
analyzed by densitometry. M1 mRNA levels were evalu-
ated by referring three densitometric values in the linear
range obtained with the M1 PCR products to those
obtained with the standard b-actin PCR products, and
normalizing for the relevant cDNA volumes.
2.9. Binding assay-membrane preparation
Male mice used for the [3H]telenzepine binding assays
were killed by decapitation 24 h after the last i.c.v.
injection of aODN, dODN or vehicle. The brain was
removed, rinsed with ice-cold 0.9% saline solution and
dissected into two regions; cortex and hippocampus.
Tissues were homogenized in 40 vol. Hepes buffer
containing 20 mM Hepes, 100 mM NaCl, 10 mM MgCl2
and 0.01 mM phenyl-methyl-sulfonil-fluoride (PMSF),
pH7.4 for 15 s using an Ultraturrax homogenizer at
half of the maximum speed. Homogenates were centrifu-
gated at 1000g for 5 min; supernatants were again
centrifuged at 48 000g for 30 min and the resultant
sediments were immediately frozen at 80°C until
binding experiments were performed.
2.10. Ligand binding assay
Frozen pellets were dispersed in Hepes buffer and then
spun at 48 000g for 30 min. The resulting pellets were
rehomogenized in the above-mentioned buffer and used
for the binding assays; an aliquot was taken for protein
determinations. Aliquots of membranes (0.4–0.6 mg
ml1) were incubated in a final vol. of 0.5 ml ligands in
Hepes buffer at 37°C for 2 h; [3H]telenzepine was present
at 0.4 nM in tubes containing increasing concentrations
(0.3–10 000 nM) of unlabeled telenzepine and at
0.05–0.4 nM in tubes without unlabeled ligand. All
measurements were obtained in duplicate. After
incubation, bound radioactivity was separated by
filtration through Whatman GF:C filters presoaked in
0.1% polyethyleneimine (PEI) using the Brandel M-48R
cell harvester (Gaithersburg, MD). Filters were washed
twice with 5 ml of 50 mM Tris–HCl buffer, pH7.4
containing 10 mM MgCl2 and counted in 5 ml of
FilterCount (Packard) in a liquid scintillation counter
TRI-CARB 1900 TR (Packard). Protein content was
measured using the Pierce protein assay reagent (Pierce
Chemical, Rockford, IL), according to the standard
assay procedure recommended by the manufacturer and
based on the method of Bradford (1976) using bovine
serum albumin as a standard.
2.11. Data analysis
Sequence comparisons of both aODN and RT-PCR
primers with the database were carried out by the
FASTA program. All experimental results are given as
the mean9SEM. An analysis of variance ANOVA,
followed by Fisher’s Protected Least Significant Differ-
ence procedure for post-hoc comparison, were used to
verify significance between two means of behavioral
results. Data were analyzed with the StatView software
for the Macintosh. The statistical significance of RT-
PCR was obtained with the Student’s t-test. The binding
data were evaluated quantitatively using the Ligand
(Munson and Rodbard, 1980) computer program; this
type of analysis provides optimal estimates of binding
parameters (affinity constants, binding capacities, non
specific binding). P valuesB0.05 were considered
significant.
2.12. Drugs
The following drugs were used: scopolamine
hydrobromide (Sigma, Italy); dicyclomine hydrochloride
(Le Petit, Italy); S-( )-ET 126 (S-( )-a-(hydroxyme-
thyl)benzene-acetic acid 1-methyl-4-piperidinyl ester)
prepared in the Department of Pharmaceutical Sciences
of Florence; pirenzepine dihydrochloride (RBI, Italy);
[3H]telenzepine (DuPont NEN, Italy); D-ampheta-
mine (De Angeli, Italy). Other chemicals were of
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the highest quality commercially available.Drugs were
dissolved in isotonic (NaCl 0.9%) saline solution imme-
diately before use. Drug concentrations were prepared
so that the necessary dose could be administered in a
volume of 5 ml per mouse by intracerebroventricular
(i.c.v.) injection and 10 ml kg1 by subcutaneous (s.c.)
injection.
3. Results
3.1. Design of oligonucleotides
Considering that the translation start sites of mR-
NAs are particularly prone to aODN action (Good-
child, 1989; Stein and Cheng, 1993), we compared the
sequence encompassing this site among the murine
known muscarinic receptors gene family, to design a
specific antimouse M1 aODN. We noted that a region
of 18 bases comprising the translation start site region
of the mouse M1 mRNA (Shapiro et al., 1988) is
endowed with a very low sequence homology even with
the nearest other members of the muscarinic receptor
family. We therefore chose this sequence to define an
aODN targeting the M1 murine mRNA. A homology
search in the Genbank database confirmed the absolute
specificity of this aODN. Considering the described
sequence-independent, non-antisense effects of ODNs
(Storey et al., 1991; Gao et al., 1992; Blagosklonny and
Neckers, 1994; Schick et al., 1995), we designed a fully
degenerated phosphorothioate capped phosphodiester
ODN as the most suitable control for these potentially
confusing effects. The fully degenerated 18-mer is a
collection of about 31014 different molecular species.
At concentrations achieved in the nanomolar to micro-
molar range in in vitro antisense experiments, every
species, i.e. every ODN of defined sequence, was
present at the site of action at a concentration less than
1018 M, which is totally insufficient to achieve any
antisense, or generally sequence-dependent, cellular ef-
fect. Therefore, if ODN i.c.v. administration per se had
achieved any biological response, this would have been
present in ODN-treated controls.
3.2. Amnesic effect of aODN to M1 muscarinic
receptor
Mice were pretreated with a single i.c.v. injection of
aODN, dODN or vehicle on days 1, 4 and 7. The effect
of aODN pretreatment on memory processes was then
evaluated in the mouse passive avoidance test.
At the dose of 0.3 nmol per i.c.v. injection, aODN
did not significantly affect the entrance latency into the
dark compartment (Fig. 1), whereas at the dose of 1.0
and 2.0 nmol per i.c.v. injection, aODN produced
amnesia (Fig. 1). This effect was detected 24 h after the
last i.c.v. injection. No difference in the amnesic effect
produced by the two effective doses of aODN was
revealed (Fig. 1). Therefore, higher doses of aODN
were not investigated.
Experiments were performed 24 h after the end of
ODN treatment since a time-course study showed that
the maximum amnesic effect was reached 24 h after the
last i.c.v. injection at the dose of 2.0 nmol per i.c.v.
injection and then it decreased (Fig. 2). However, am-
nesia induced by aODN to M1 receptors appeared at 12
h and was also statistically significant at 48 and 72 h
(Fig. 2). In contrast, on day 7, the impairment of
cognitive processes produced by aODN disappeared
(Fig. 2).
Pretreatment with the dODN did not modify the
entrance latency into the dark compartment in com-
Fig. 4. Lack of effect of an aODN to M1 gene in comparison with
D-amphetamine in the hole board test. Mice received a single i.c.v.
injection of aODN, dODN, saline or vehicle on day 1, 4 and 7. The
responses for saline, vehicle, aODN and dODN were recorded 24 h
after the last i.c.v. injection. D-Amphetamine response was recorded
15–25 min after administration. The number of mice is inside the
column. * PB0.01 in comparison with saline-treated mice.
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Fig. 5. Quantitative RT-PCR analysis of M1 mRNA. Total RNA was
extracted from the brains of three mice for each group behaviorally
processed 24 h after the last ODN injection. M1 and b-actin mRNA
were submitted to RT-PCR as reported in the ‘experimental proce-
dures’. aODN and dODN were administered i.c.v. on day 1, 4 and 7.
(A) RT-PCR analysis of increasing cDNA aliquots of retrotran-
scribed RNA. Primers specific for murine M1 mRNA and b-actin
mRNA were used. (B) Quantification of M1 mRNA steady-state
levels performed by densitometric analysis of PCR products taken in
the range of linearity. Data are the mean of three determinations.
Values are expressed as a percentage (%).
3.3. Effect of aODN on rota-rod and hole-board tests
Mice pretreated with aODN (2.0 nmol per injec-
tion) or dODN (2.0 nmol per injection) were evalu-
ated for motor coordination, spontaneous motility
and inspection activity by use of the rota-rod (Table
1) and hole board (Fig. 4) tests. Both tests were car-
ried out 24 h after the last i.c.v. injection. The motor
coordination of animals pretreated with aODN and
dODN, which was evaluated using the rota-rod test,
was not significantly impaired in comparison with sa-
line- and vehicle-treated mice (Table 1). Each group
progressively reduced its number of falls since mice
learned how to balance on the rotating rod.
The spontaneous motility and inspection activity of
mice was unmodified by pretreatment with aODN
(2.0 nmol per injection) or dODN (2.0 nmol per in-
jection) as revealed by the hole board test (Fig. 4) in
comparison with saline- and vehicle-treated mice. In
the same experimental conditions D-amphetamine (1
mg kg1 s.c.) increased both parameters evaluated.
3.4. Effect of aODN on specific inhibition of M1 gene
expression
The lowering of M1 mRNA following aODN ad-
ministration as an index of M1 gene expression inacti-
vation was quantified by RT-PCR. Before
quantification, RT products were tested for possible
genomic DNA contamination. For this purpose, am-
plification products—a segment of 192 bp for mouse
M1 cDNA and of bp 232 for b-actin cDNA—were
visualized by agarose gel electrophoresis. Qualitative
gel analysis showed bands of the expected length and
an absence of any contamination in the negative con-
trols (data not shown). Quantitative results of M1
mRNA brain levels following aODN mouse treatment
confirmed that phenotypic effects of anti-M1 aODN
on cognitive processes were actually due to the spe-
cific inhibition of M1 gene expression (Fig. 5). Fig. 5,
panels A and B, shows that the M1 mRNA:b-actin
mRNA ratio was sharply lowered in anti-M1 aODN-
treated mice as compared to dODN-treated mice.
3.5. Determination of M1 receptor protein brain le6els
Saturation analysis demonstrated that [3H]telenzepine
binds with high affinity and saturable manner to a
homogeneous class of sites in membranes from brain,
hippocampus and cortex of dODN- and aODN-treated
mice. A decrease in [3H]telenzepine binding was observed
in the cortex even if statistical significance was reached
only in the hippocampus (Table 2). [3H]telenzepine
binding in the whole brain was not appreciably affected
by the treatment (data not shown); in any case KD values
remained unaffected (Table 2).
parison with mice injected with vehicle i.c.v. as shown
in Fig. 1.
The intensity of the amnesia produced by aODN
treatment was comparable to that exhibited by the
non selective muscarinic antagonist scopolamine (2 mg
per mouse i.c.v.) and the M1 selective antagonists
pirenzepine (0.1 mg per mouse i.c.v.), dicyclomine (1
mg per mouse i.c.v.) and S-( )-ET-126 (0.1 mg per
mouse i.c.v.) (Fig. 3). The antimuscarinic drugs were
administered immediately after the training session.
The i.c.v. injection of vehicle or saline did not
modify animals’ performance in the mouse passive
avoidance test in comparison with naive mice (Fig.
3).
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Table 2
[3H]telenzepine binding to mouse cortex and hippocampus membranes by anti-M1 ODN (aODN) and degenerate ODN (dODN)a
Treatment Cortex Hippocampus
Bmax (fmol:mg protein) KD (nM)Bmax (fmol:mg protein)KD (nM)
956.27930.32 1.4090.10dODN (n3) 1136.91952.85 2.2390.29
1.9590.12 822.79934.82*aODN (n3) 1066.21922.58 1.2790.10
a Binding experiments were performed 24 h after the last i.c.v. injection. Values indicate mean9SEM.
* PB0.05 versus dODN-treated mice.
4. Discussion
The present study provides evidence of the funda-
mental role played by the M1 muscarinic receptor sub-
type in cognitive processes. Pretreatment by i.c.v.
administration of an antisense to the M1 gene coding
for the mouse M1 receptor impairs passive avoidance
learning in mice. At active doses, aODN to M1 receptor
does not modify animal gross behavior nor impair
motor coordination, spontaneous motility and inspec-
tion activity.
The maximum amnesic effect obtained following in-
jection of an aODN to the M1 receptor has similar
intensity to that produced by the unselective muscarinic
antagonist scopolamine as well as the selective M1
antagonists pirenzepine, dicyclomine and S-( )-ET
126. These data confirm the important role played by
M1 receptors in the modulation of mnemonic functions
(Section 1). Furthermore, the employment of an aODN
to the M1 receptor allows clear elucidation of the role
of the M1 receptor in memory processes without any
potential interference due to interaction with the other
muscarinic receptor subtypes. The above-mentioned M1
receptor antagonists, even if they are the most selective
M1:M2–M3 compounds available, are endowed with
selectivity for M1 receptors comprising between 3 (for
dicyclomine; Giachetti et al., 1986) and 176 (for S-( )-
ET 126; Ghelardini et al., 1996). This selectivity ratio
does not exclude the fact that, at doses active on
cognitive processes, these compounds can also interact
with other muscarinic receptor subtypes such as M2,
that are involved in modulation of learning and mem-
ory (Packard et al., 1990; Sen and Bhattacharya, 1991;
Gualtieri et al., 1995).
The aODN treatment induces a transient anterograde
amnesic effect since the impairment of passive avoid-
ance performance disappears 7 days after the last i.c.v.
injection of the aODN. This return to normal memory
function implies both the total reversal of aODN-in-
duced specific inhibition of M1 gene expression and a
lack of damage or toxicity associated with aODN treat-
ment. In comparison with naive and saline i.c.v. treat-
ment, dODN and vehicle treatments do not modify the
latency to enter the dark compartment, ruling out the
possibility that the antagonism exerted by aODN could
be caused by sequence-independent effects on cerebral
structures. This claim is supported by results obtained
from the quantitative RT-PCR analysis of ODN effects
on M1 gene expression. Degenerated ODN does not
modify M1 mRNA brain levels, whereas the anti-M1
aODN specifically lowers M1 mRNA brain levels.
A reduction in M1 mRNA levels, but not in M1
receptors, is observed by processing the whole brain.
Considering that M1 receptors are expressed at the
highest levels in particular brain areas, such as the
cortex and hippocampus (Cortes and Palacios, 1986;
Cortes et al., 1986), we investigated the effects pro-
duced by aODN treatment in M1 receptor levels in
these two areas. These regions appear to be the most
appropriate also because they are greatly involved in
the modulation of memory processes (Zola-Morgan
and Squire, 1993). By performing binding experiments
in the hippocampus and cortex of anti-M1 treated mice,
we documented a reduction in the binding sites of
[3H]-telenzepine to M1 receptors in both cerebral struc-
tures. These results are in agreement with previous
findings in which a reduction of [3H]-QNB binding in
rat cortex and hippocampus is observed after treatment
with an aODN to the m1 muscarinic receptor mRNA
(Zang et al., 1994). Fewer M1 receptors in the
hippocampus of anti-M1 aODN-treated mice confirms
the importance of a complete integrity and functional-
ity of M1 receptors in the modulation of memory
functions. In fact, a lack of expression of M1 receptors,
as well as the intrahippocampal injection of scopo-
lamine (Brito et al., 1983), atropine (Singh et al., 1974)
and pirenzepine (Messer et al., 1985), produce amnesia.
The amnesic effect in amnesic and Alzheimer’s patients
is reported to be ascribed to a disturbance of declara-
tive long-term memory or explicit memory, and not to
non-declarative memory, in which classical condition-
ing tasks like passive avoidance are classified (Zola-
Morgan and Squire, 1993; Squire and Zola, 1996).
These data could mean that the reduction of M1 recep-
tor levels seen in the cortex and hippocampus of
aODN-treated mice might be observed because the M1
receptors are expressed at the highest levels in these two
structures. The detection of an amesic effect in anti-M1
treated mice in passive avoidance experiments might
indicate that the M1 muscarinic receptor subtype could
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not play a key role in memory processes through the
hippocampus, but it may play a modulating role
through other structures involved in learning and
memory.
In our experimental conditions, the anti-M1 aODN
does not cause any detectable modification in mouse
gross behavior. Moreover, mice treated with the highest
dose used of aODN have unimpaired motor coordina-
tion in comparison with dODN- and vehicle-treated
groups or naive mice. Repetition of the test session
every 15 min for four times induces a progressively
slight decrease in the number of falls in control animals
as well as in aODN- and dODN-treated mice. By
contrast, the lack of variation, or an increase in the
number of falls after treatment indicates impaired
mouse motor coordination that could lead to a misin-
terpretation of the results obtained in the passive avoid-
ance test. Since during the passive avoidance test mice
have to move from the light to the dark compartment
of a light-dark box, the treatment must not modify
either spontaneous motility or inspection activity of
animals. The lack of effect by aODN and dODN
treatment in the hole board test, which measures both
the above-mentioned parameters, excludes that the ob-
served amnesia underlies a behavioral side effect pro-
duced by the i.c.v. injection of oligos.
Seen as a whole, our data indicate that the M1
muscarinic receptor subtype plays a key role in the
modulation of memory functions in mice, and also
suggests the actual possibility of modulating receptor
activity in laboratory animals by the aODN strategy.
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